ERBB2 and neoplasm: Such heterogeniety is also apparent in our HER-2 dendritic cell vaccine trials for DCIS [8, 9, 10] where 18.5% of subjects showed complete pathological responses (i.e. all observable tumor cells died) while other subjects showed apparent partial reductions in tumor volume, while still others showed no discernable reductions in disease at all.